What guidance did Apyx Medical's management provide for the next earnings period?

What is Apyx Medical's latest dividend and current dividend yield?

What is the market's earnings forecast for Apyx Medical next quarter?

Did Apyx Medical beat or miss consensus estimates last quarter?

What does Apyx Medical do and what are its main business segments?

What factors drove the changes in Apyx Medical's revenue and profit?

What is the revenue and EPS growth rate for Apyx Medical year over year?

What were the key takeaways from Apyx Medical's earnings call?

Focus on AYON adoption rates, Surgical Aesthetics guidance, and cash flow management.

The company reported Q3 2025 revenue of $12.9 million, up 12% YoY driven by AYON system adoption. Surgical Aesthetics segment revenue reached $11.1 million, with AYON handpiece sales leading the way. CFO noted Q4 guidance of $43-45 million for Surgical Aesthetics. AYON adoption is accelerating with KOLs highlighting its integration into clinical workflows. The company is prioritizing U.S. installations ahead of international expansion in 2026. Key metrics: Q3 GAAP net loss of $2.8 million, with focus on cash management and cost control. Investors should monitor AYON's attach rates and pipeline visibility into Q4. The company reaffirmed 2025 Surgical Aesthetics guidance of $43-45 million, with AYON adoption in the U.S. to drive Q4. International expansion in 2026.

APYX

APYX fundamentals

You can ask Aime